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Abstract
Preschool children and infants frequently suffer wheezy 
episodes, mostly associated with viral respiratory tract infections. 
There is no evidence to support the use of maintenance low 
dose inhaled corticosteroids to prevent or manage episodic 
mild wheeze caused by such viral infections. However, infants 
and young children with recurrent episodic wheeze and a 
positive asthma risk index (i.e. risk factors associated with a 
predisposition for the future development of asthma) should 
be considered for a short, three-month trial of an inhaled 
corticosteroid. Failure to respond to an inhaled corticosteroid 
should prompt its discontinuation and not an increase in the 
drug dose. Persistent wheezing should suggest a possibility 
of an alternate diagnosis and the child should be referred for 
further investigations. Some recurrently wheezy infants and 
children simply do not respond to inhaled corticosteroids and 
most symptoms remit spontaneously after the age of five years, 
especially among those who do not have an atopic predisposition. 
The use of large doses of inhaled corticosteroids in young 
children whose wheezing persists should be discouraged due 
to the significant risk of long-term effects.
Introduction
The prevalence of asthma and other atopic diseases has 
increased dramatically worldwide over the last few decades but 
some investigators argue that the condition seems to be reaching 
a plateau.1  However, asthma is still responsible for a significant 
degree of morbidity and to a lesser degree of mortality in the 
paediatric age group. The principles of management of asthma 
are aimed at the relief of symptoms and the suppression of the 
underlying chronic inflammatory processes in the airways. To 
this end, no drugs have been more successful in this than inhaled 
corticosteroids (ICS) and their use has heralded a new, effective 
and relatively safe management for the many patients who 
suffer from asthma. There is no doubt about the effectiveness 
of steroids in patients with asthma but the use of long-term 
inhaled steroids in pre-school age children and infants has 
raised several questions as to their effectiveness and possible 
long-term complications. 
The management of wheeze in infancy is largely ignored in 
the asthma guidelines (Global Initiative for Asthma, GINA2, and 
British Thoracic Society3, BTS), despite evidence of a differing 
aetiology and response to treatment when compared to older 
children.
Despite over one hundred therapeutic studies of 
bronchodilators and corticosteroids in infants and 40 studies 
using corticosteroids, clear consensus on best practice is lacking. 
Methodological issues, inappropriate outcome measures, and 
conflicting results have contributed to the uncertainty.4 
This article will address the problem of wheezing in young 
infants and pre-school age children and review the literature on 
the use of ICS in the early years of life.
Background
Many young children and infants wheeze during the course 
of viral respiratory infections; however the pathogenesis of 
these episodes and their relation to the development of asthma 
later in life are not well understood.5  In a prospective study, 
the factors affecting wheezing before the age of three years and 
their relation to wheezing at six years of age were investigated 
in 1246 newborns in Tucson, Arizona. These children were 
assessed in infancy with measurement of cord-serum IgE levels, 
pulmonary-function testing before any lower respiratory tract 
illness had occurred, measurement of serum IgE levels at nine 
months of age, and questionnaires, completed by the children’s 
parents when their offspring were one year old. Re-assessment 
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was performed again at six years of age.  At the age of six, 51.5 % 
had never wheezed, 19.9 % had had at least one lower respiratory 
tract illness with wheezing during the first three years of life but 
had no wheezing at six years of age, 15.0 % had no wheezing 
before the age of three years but had wheezing at the age of six 
years, while 13.7 % had wheezing both before three years of age 
and at six years of age. 
Children who had wheezing before three years of age but not 
at the age of six, had diminished airway function both before 
the age of one and at the age of six years and were more likely 
than the other children to have mothers who smoked, but not 
mothers with asthma; they did not have elevated serum IgE 
levels or skin-test reactivity. Children who started wheezing in 
early life and continued to wheeze at the age of six were more 
likely than the children who had never wheezed to have mothers 
with a history of asthma (p < 0.001), to have elevated serum 
IgE levels (p < 0.01) and normal lung function in the first year 
of life, and to have elevated serum IgE levels (p < 0.001) and 
diminished lung function (p < 0.01) at six years of age. 
This long-term study has shown that the problem of 
wheezing in infancy and early childhood consists of two 
main groups of children. Patients with a parental history of 
asthma and serological markers for atopy were more likely 
to persistently wheeze after the age of six years. Patients who 
wheezed in infancy but did not have a parental history of asthma 
or markers for atopy were less likely to wheeze after the sixth 
year of life.
The majority of infants with wheezing have transient 
conditions associated with diminished airway function at birth 
and do not have increased risks of asthma or allergies later in life. 
In a substantial minority of infants, however, wheezing episodes 
are probably related to a predisposition to asthma.
There are several other studies that have investigated the 
natural history of wheezing disorders in infants and young 
children and results similar to those obtained by Martinez et 
al.6
Airway remodeling
Airway remodeling in established adult asthmatics and its 
subsequent irreversible negative effect on lung function has 
been addressed by several studies. The extrapolation of adult 
data to the paediatric age group is not possible as the duration 
and severity of symptoms are not common to both groups of 
patients. Although there are very few interventional studies with 
bronchoscopy and biopsy in children, several studies looking at 
long-term lung function have been performed.7,8  The conclusion 
from most of these studies was that the longer asthma symptoms 
persist and the longer the delay in introducing ICS, the more 
likely is the risk of irreversible changes in lung function.
The conclusions from several similar studies performed in 
the late 1990’s lead to the concept of airway remodeling and 
long-term irreversible change in lung function. As a result, 
early introduction of inhaled corticosteroids was advocated and 
implemented. There is no doubt that this strategy is beneficial 
when asthma is established, especially when symptoms are 
severe. It is of concern that in pre-school age children with 
wheezing, the effects of long-term ICS are not clear, when 
benefits and side-effects are considered. Little is known about 
the airway pathology of wheezing disorders in infants and 
preschool children, partly owing to the difficulty of undertaking 
invasive studies in this age group. If endobronchial biopsy is to 
be used to investigate the pathology of wheezing disorders in 
infants and preschool children, it is essential that the procedure 
is safe and that good quality biopsies can be obtained. 
Asthma management guidelines are unsuitable for young 
children. Over the past decade, a number of guidelines have 
been published that are intended to help the clinician manage 
patients with asthma.9  Many guidelines recommend managing 
infants as if they were simply smaller versions of adults; with 
reference to preschool children, the GINA guidelines advice 
the use of a treatment algorithm similar to that used in school 
children, which, in fact, uses the same classification of disease 
severity as that used for adults. In the BTS guidelines, there is a 
warning concerning problems in the management of very young 
children that emphasizes the difficulty of diagnosis, the fact that 
most treatments have very poor efficacy, and that there are very 
few controlled trials of treatment in this age group. 
Paediatricians have a particular problem in evaluating the 
severity of asthma in infants and young children, however, in 
the guidelines, this problem is ignored. Wheezing in infancy 
and early childhood cannot be fitted into the classification of 
asthma severity used by the guidelines aimed at treating older 
children and adults. Management should take into account the 
age and background of the child, the day-to-day disturbance 
to the life of the child and the family due to the wheezing or 
coughing attacks, as well as the response to a graded treatment 
strategy. The very common complaints of wheeze, cough, noisy 
breathing, and respiratory distress may also occur in young 
children with potentially more serious problems, such as foreign 
body aspiration, congenital airway or cardiac anomalies, and 
cystic fibrosis. The persistence of symptoms without remission 
and failure to thrive should suggest the possibility of a diagnosis 
other than asthma in a young child with atypical wheezing.9
Identification of infants 
and young children at risk of asthma
The majority of young children with wheezy lower respiratory 
tract infections have transient symptoms and a benign outcome. 
The health-related ethical and financial implications of blanket 
treatment of all young children and infants who wheeze is highly 
questionable. The task of identifying subjects at risk of future 
asthma in early life is hampered by the complex nature of the 
problem. Retrospective studies have helped identify markers 
and risk factors, which help the clinician answer the dilemma 
of which infant should be treated. As importantly, investigators 
who want to determine whether early treatment with anti-
asthma therapy may change the natural course of the disease 
also need tools to identify those infants who may truly respond 
to such therapy.10
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In 1999 Martinez proposed an algorithm (Table 1) similar 
to the Jones criteria for the diagnosis of rheumatic fever.5 The 
major and minor criteria are defined by their relative predictive 
power and those infants and young children with a positive 
asthma risk index should be considered at high risk for persistent 
wheezing after the age of six years and should be given a trial 
of inhaled corticosteroids. The criteria will also hopefully 
standardize selection of young children for future prospective 
studies on the effectiveness of ICS in the management of the 
young child with recurrent wheezing.
Studies on use of inhaled corticosteroids 
in young children
One of the major methodological deficiencies is that most 
studies have failed to make a distinction between infants 
and young children with an atopic predisposition and those 
with simple recurrent viral associated wheezing. In a study 
by Chavasse et al., 148 U.K. based consultant paediatricians 
returned a questionnaire on how they manage wheezy 
infants. Salbutamol was the preferred bronchodilator for 
recurrent wheeze, whereas ipratropium was preferred in viral 
bronchiolitis. Doses of both medications varied widely and most 
respondents considered both inhaled and oral corticosteroids. 
There was an alarming range of doses unsupported by the 
literature and apparently paediatricians do not adhere to the 
current guidelines for asthma when treating wheezy infants. 
Inhaled corticosteroids (ICS) improve symptoms and reduce 
the number of exacerbations, even in toddlers with persistent 
wheezing, which strongly suggests the inflammatory nature 
of the disease. However, ICS generally do not provide full 
control in this age group.11,12  It is not known whether this is 
due to insufficient patient adherence, too low a dose of steroids, 
pharmacogenetic heterogeneity, or a distinct pathology in early 
asthma or in subgroups of wheezy young children.   There are 
few reports on the inflammatory nature of persistent wheezing 
in young preschool children. 
Recurrent episodic wheeze in association with viral upper 
respiratory tract infection (URTI) is a specific clinical illness 
distinct from persistent atopic asthma.
A wheeze that is recurrent and caused by a viral upper 
respiratory tract infection (URTI) is different to asthma. 
Episodic recurrent wheezing happens in children who have no 
symptoms in between episodes and is different to wheezing that 
is persistent. A Cochrane review of trials found that high-dose 
inhaled corticosteroids help treat mild episodic viral wheeze 
of childhood however there is no evidence to support the use 
of maintenance low-dose inhaled corticosteroids to prevent or 
manage episodic mild wheeze caused by viral infection. 13
Malta
The local situation reflects this theme in that children may 
be inappropriately placed on ICS therapy, and this was clearly 
demonstrated in a local audit performed in 2002.14 The study 
consisted of a retrospective analysis of clinical notes of 484 
patients, less than 5 years of age who were started on inhaled 
steroids in the Outpatients Department in 2001. All new 
applications (468) were reviewed for demographic data and type 
of inhaled steroids prescribed. Out of these new applications, the 
clinical notes of 100 randomly selected patients were examined 
in detail.
These were further reviewed to identify when and what 
inhaled steroids were started and whether basic criteria for the 
introduction of inhaled corticosteroids were met. Finally an 
asthma risk index was calculated (as per Table 1) and this was 
related to the various age groups and the need for introduction 
of long-term inhaled steroid treatment.
Analysis of notes of 
00 randomly selected patients
The number of patients less than two years of age totaled 
174 while 340 patients were between the ages of two and five 
years. The patients less than two years of age included 96 who 
were less than one year old. 
From a total of 100 patients 68% were male and 32% female. 
The age range was from 1 month to 60 months with a mean age 
of 22.7 months. 
The total childhood population (Maltese) less than five years 
of age in 2001 was 21,748, and the number of children less than 
five years receiving inhaled corticosteroids was 484 (2.23%). Of 
the total number of patients whose notes were examined 45% 
had a negative asthma risk index while 55% satisfied criteria for 
a trial of prophylactic treatment.
The mean ages of both groups were 25 months and 22 
months respectively. 
It is clear from the results of the audit that an alarming 
percentage of children (2.23%) under the age of five years have 
been prescribed long-term inhaled corticosteroids without 
satisfying minimum criteria or adequate follow to assess the 
true impact of ICS on their wheezing.
Table 1: Defining the asthma risk index. Children who 
meet one of the first two major criteria and any other 
of the major criteria and those who meet one of the first 
two major criteria and any two minor criteria should be 
considered to have a positive asthma risk index
Major criteria Minor criteria
1. Hospitalization for severe  1. Doctor diagnosed
 wheezing / bronchiolitis.  allergic rhinitis.
 
2. At least three wheezing  2. Wheezing apart 
 LRI’s during previous   from colds.
 six months.
 
3. Parental history of asthma. 3. Eosinophilia >5% 
 
4. Atopic dermatitis.  4. Male sex.
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Management approach
Wheezing in infancy and early childhood cannot be fitted 
into the classification of asthma severity used by the guidelines 
for older children and adults. Management should take into 
account the age, the disturbance to the everyday life of the child 
and the family due to the wheezing or coughing attacks, and the 
response to a graded treatment approach.
There will be symptom-free intervals lasting for weeks or 
months between attacks, during which treatment can be reduced or 
stopped. Some wheezy infants and children simply do not respond 
to treatment without necessarily having an alternative diagnosis. 
When a child is not responding to treatment, especially an inhaled 
corticosteroid, there is no reason for it to be continued. 
Treatment is given, as needed using an inhaled selective 
beta
2
-agonist bronchodilator until the attack is over using an 
appropriate inhalation device. A short course of corticosteroids 
may be useful especially in patients who have a recurrent 
history of wheezing. Those infants and young children with 
recurrent episodic wheeze and a positive asthma risk index 
should be considered for a short three-month trial of an inhaled 
corticosteroid. 
When a child is not responding to an inhaled corticosteroid 
there is no reason for it to be continued. Persistent wheezing 
should suggest a possibility of an alternate diagnosis and the 
child should be referred for further investigations. Some typical 
wheezy infants and children simply do not respond to treatment 
without necessarily having an alternative diagnosis. Most of 
these young patients remit spontaneously after the age of five 
years especially those without an atopic predisposition. The use 
of large doses of inhaled corticosteroids in young children whose 
wheezing persists should be discouraged.
Conclusion
Persistent wheezing is the most common chronic disease 
in young pre-school children and a considerable burden to the 
child and health services. It is also a diagnostic and therapeutic 
challenge to health care providers. This is an area in which there 
is minimal investigation and evidence of efficacy of therapeutic 
measures and hence little data on which to make treatment 
decisions. Subgrouping wheezy children is helpful and may be 
attempted from the clinical picture and predisposition to atopy. 
Inhaled corticosteroids provide only modest beneficial effects 
in such children and further studies are required to define 
their role. The use of criteria for the identification of an atopic 
predisposition and hence a positive risk of developing asthma 
in later life should be encouraged.   
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